Vai al contenuto principale della pagina
| Autore: |
Allison Simon J
|
| Titolo: |
Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action
|
| Pubblicazione: | MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica: | 1 online resource (206 p.) |
| Soggetto topico: | History of engineering & technology |
| Technology: general issues | |
| Soggetto non controllato: | 5-FU resistance |
| 8-hydroxydaidzein | |
| affibody drug conjugate (AffiDC) | |
| affibody molecule | |
| albumin binding domain | |
| angiogenesis | |
| anti-cancer agent | |
| anticancer drug | |
| apoptosis | |
| AQ4N | |
| autophagy | |
| B-lactam steroid alkylators | |
| BCR-ABL | |
| biomarker | |
| bioprecursor | |
| breast cancer | |
| BxPC-3 | |
| c-myc | |
| cancer hallmarks | |
| CCN1 | |
| colorectal cancer | |
| Connectivity Map | |
| CYP1A1 | |
| CYP1B1 | |
| CYP2W1 | |
| Cytochrome P450 | |
| DM1 | |
| drug repurposing | |
| duocarmycin | |
| EGFR tyrosine kinase inhibitor | |
| emtansine | |
| expression | |
| gene silencing | |
| Genomics of Drug Sensitivity in Cancer | |
| glioblastoma | |
| HepG2 | |
| Huh7 | |
| human epidermal growth factor receptor 3 (HER3) | |
| hybrid steroidal alkylating agents | |
| in vivo imaging | |
| invasion | |
| isatin sulfonamides | |
| K562 | |
| MAPK | |
| mesenchymal-amoeboid transition | |
| microtubule acetylation | |
| migration | |
| molecular docking | |
| n/a | |
| nanoparticles | |
| nanosystems | |
| NF-κB | |
| oncogene | |
| ovarian cancer | |
| phortress | |
| photon upconversion | |
| PLGA | |
| poly (ADP-ribose) polymerase inhibitors | |
| prodrug | |
| RNA interference | |
| siRNA | |
| synthetic lethality | |
| triple-negative breast cancer | |
| triplet-triplet annihilation | |
| Persona (resp. second.): | AllisonSimon J |
| Sommario/riassunto: | Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue 'Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action', provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. |
| Altri titoli varianti: | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism |
| Titolo autorizzato: | Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action ![]() |
| ISBN: | 3-0365-5222-7 |
| Formato: | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910619465503321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |